EGFR29 Mutation Test Kit

Product Overview

The DXS EGFR29 Mutation Test kit is a highly selective assay for the detection of the 29 most common somatic mutations in the Epidermal Growth Factor Receptor (EGFR) gene*.

Recent studies into non-small cell lung cancer have shown that some patients carry somatic mutations in the epidermal growth factor receptor gene (EGFR). These mutations correlate with responsiveness to tyrosine kinase inhibitors such as gefitinib and erlotinib, with some mutations having a sensitising effect and others being linked to resistance.

This kit enables the detection of the following mutations against a background of wild type genomic DNA in a real time PCR assay.

  • 19 Deletions in exon 19
  • T790M
  • L858R
  • L861Q
  • G719X (detects the presence of G719S, G719A or G719C but does not distinguish between them)
  • S768I
  • 3 insertions in exon 20 (detects the presence of any of 3 insertions but does not distinguish between them).

These mutations cover a high percentage of all mutations seen in the EGFR gene in cancer samples.

 

ss

Diagram to show location of alleles detected by the DxS EGFR 29 Mutation Test Kit
Extended Mutation Coverage

 
Intended Use

The real-time PCR kit for the detection of mutations in the EGFR gene is for research purposes only.

 
Samples

Sample types include human genomic DNA from fresh, frozen or paraffin embedded tissue.

 
Summary

EGFR Mutation Test Kit is:

  • Qualitative; accurately detects SNPs, insertions and deletions
  • Optimised to detect mutated sequences in an excess of normal DNA
  • Based on validated technologies; Scorpions™ for real-time detection and ARMS™ (allele specific PCR)
  • Can detect 1% of mutant in a background of wild type genomic DNA
  • Compatible with most real-time PCR instruments

* The mutations in EGFR kit were the 29 most frequent in the COSMIC database (http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=gene;ln=EGFR) at the end of March 2006

 
Further details and pricing upon request:

T: +44 (0) 161 606 7201
E: sales@dxsgenotyping.com

 

References

1. Guillermo Paez J, Pasi A.Jänne, Jeffrey C.Lee et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Sciencexpress , 1-10. 4 A.D.
Ref Type: Generic

2. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.

3. Raffaella Sordella, Daphne W.Bell, Daniel A.Haber, Jeffrey Settleman.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways. Science 305, 1163-1167.
Ref Type: Generic

4. Kimura H, Kasahara K, Kawaishi M et al.  Detection of Epidermal Growth Factor  Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non Small-Cell Lung Cancer. Clin Cancer Res 2006;12(13) July 2006.

5. Newton CR, Graham A, Heptinstall LE et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989; 17: 2503-2516.

6. Whitcombe D, Theaker J, Guy SP, Brown T, Little S. Detection of PCR products using self-probing amplicons and fluorescence. Nat.Biotechnol. 1999; 17: 804-807.

 

 
top